{"protocolSection":{"identificationModule":{"nctId":"NCT00531934","orgStudyIdInfo":{"id":"ML20829"},"organization":{"fullName":"Hoffmann-La Roche","class":"INDUSTRY"},"briefTitle":"A Study of Management of Tarceva - Induced Rash in Patients With Non-Small Cell Lung Cancer.","officialTitle":"A Randomized, Open Label Study to Evaluate the Effect of Doxycycline on Tarceva-induced Skin Rash in Patients With Non-small Cell Lung Cancer After Failure of First Line Chemotherapy"},"statusModule":{"statusVerifiedDate":"2015-02","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2007-10"},"primaryCompletionDateStruct":{"date":"2010-08","type":"ACTUAL"},"completionDateStruct":{"date":"2010-08","type":"ACTUAL"},"studyFirstSubmitDate":"2007-09-18","studyFirstSubmitQcDate":"2007-09-18","studyFirstPostDateStruct":{"date":"2007-09-19","type":"ESTIMATED"},"resultsFirstSubmitDate":"2014-06-23","resultsFirstSubmitQcDate":"2014-08-25","resultsFirstPostDateStruct":{"date":"2014-08-26","type":"ESTIMATED"},"lastUpdateSubmitDate":"2015-02-05","lastUpdatePostDateStruct":{"date":"2015-02-25","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Hoffmann-La Roche","class":"INDUSTRY"}},"descriptionModule":{"briefSummary":"This 2 arm study will evaluate the management of Tarceva-induced skin rash in patients with non-small cell lung cancer who have failed first-line chemotherapy for advanced disease. Eligible patients will be randomized to receive a)doxycycline 100mg po daily or b)no preventative treatment; all patients will receive Tarceva 150mg/kg po daily. The anticipated time on study treatment is until disease progression or intolerable toxicity, and the target sample size is 100-500 individuals."},"conditionsModule":{"conditions":["Non-Small Cell Lung Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":147,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: Doxycline","Drug: erlotinib [Tarceva]"]},{"label":"2","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: erlotinib [Tarceva]"]}],"interventions":[{"type":"DRUG","name":"Doxycline","description":"100mg po daily","armGroupLabels":["1"]},{"type":"DRUG","name":"erlotinib [Tarceva]","description":"150mg po daily","armGroupLabels":["1","2"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Percentage of Participants With at Least One Skin Rash (Folliculitis) of Any Grade During the First 4 Months of Treatment","description":"Description of skin rash (folliculitis, including erythema, papulo-pustules, nodule, and crust) was according to Common Terminology Criteria for Adverse Events (CTCAE) version 3 scale. Medical pictures of the face (front and sides views) systematically, and of any region presenting with skin lesions were obtained. The pictures were reviewed by a centralized committee of evaluation.","timeFrame":"Days 0, 14, 28 and Months 2, 3, and 4"}],"secondaryOutcomes":[{"measure":"Number of Skin Rash (Folliculitis) Events During the First 4 Months of Treatment","description":"A cutaneous rash as folliculitis can be defined with several types including erythema, papulo-pustular and nodules.","timeFrame":"Days 0, 14, 28 and Months 2, 3, and 4"},{"measure":"Percentage of Participants With Skin Rash (Folliculitis) During the First 4 Months of Treatment By Type","description":"A cutaneous rash as folliculitis can be defined with several types including erythema, papulo-pustule, nodule, and crust.","timeFrame":"Days 0, 14, 28 and Months 2, 3, and 4"},{"measure":"Percentage of Participants With Skin Rash (Folliculitis) During the First 4 Months of Treatment By Maximal Intensity","description":"Intensity of skin rashes was classified according to CTCAE grading. Grade 1 equals (=) Macular or papular eruption or erythema without associated symptoms; Grade 2=Macular or papular eruption or erythema with pruritus or other associated symptoms; localized desquamation or other lesions covering less than (\\<)50 percent (%) of body surface area (BSA); Grade 3=Severe, generalized erythroderma or macular, papular, or vesicular eruption; desquamation.","timeFrame":"Days 0, 14, 28 and Months 2, 3, and 4"},{"measure":"Percentage of Participants With at Least One Skin Rash (Folliculitis) of Any Grade After the First 4 Months of Treatment","timeFrame":"Months 7, 10, and 12"},{"measure":"Number of Skin Rash (Folliculitis) Events After the First 4 Months of Treatment","description":"A cutaneous rash as folliculitis can be defined with several types including erythema, papulo-pustular and nodules.","timeFrame":"Months 7, 10, and 12"},{"measure":"Number of Participants With Skin Rash (Folliculitis) After the First 4 Months of Treatment By Type","description":"A cutaneous rash as folliculitis can be defined with several types including erythema, papulo-pustule, nodule, and crust.","timeFrame":"Months 7, 10, and 12"},{"measure":"Number of Participants With Skin Rash (Folliculitis) After the First 4 Months of Treatment By Intensity","description":"Intensity of skin rashes was classified according to CTCAE grading. Grade 1=Macular or papular eruption or erythema without associated symptoms; Grade 2=Macular or papular eruption or erythema with pruritus or other associated symptoms; localized desquamation or other lesions covering \\<50% of BSA; Grade 3=Severe, generalized erythroderma or macular, papular, or vesicular eruption; desquamation.","timeFrame":"Months 7, 10, and 12"},{"measure":"Time Free From Skin Rash (Folliculitis) During the First 4 Months of Treatment - Number of Participants With an Event","description":"Period without occurrence was determined as the number of days from the first dose of medication until the first appearance of folliculitis, analyzed using Kaplan-Meier analysis.","timeFrame":"Days 0, 14, 28 and Months 2, 3, and 4"},{"measure":"Time Free From Skin Rash (Folliculitis) During the First 4 Months of Treatment - Time to Event","description":"Period without occurrence was determined as the number of days from the first dose of medication until the first appearance of folliculitis, analyzed using Kaplan-Meier analysis.","timeFrame":"Days 0, 14, 28 and Months 2, 3, and 4"},{"measure":"Percentage of Participants Estimated to be Event Free at 4 Months","description":"Percentage of participants estimated to be without skin rash (folliculitis) at 4 months.","timeFrame":"Days 0, 14, 28 and Months 2, 3, and 4"},{"measure":"Time Free From Skin Rash (Folliculitis) During the Whole Treatment Period - Number of Participants With an Event","description":"Period without occurrence was determined as the number of days from the first dose of medication until the first appearance of folliculitis, analyzed using Kaplan-Meier analysis.","timeFrame":"Days 0, 14, 28 and Months 2, 3, 4, 7, 10, and 12"},{"measure":"Time Free From Skin Rash (Folliculitis) During the Whole Treatment Period - Time to Event","description":"Period without occurrence was determined as the number of days from the first dose of medication until the first appearance of folliculitis, analyzed using Kaplan-Meier analysis.","timeFrame":"Days 0, 14, 28 and Months 2, 3, 4, 7, 10, and 12"},{"measure":"Percentage of Participants Estimated to be Event Free at 12 Months","description":"Percentage of participants estimated to be without skin rash (folliculitis) at 12 months.","timeFrame":"Days 0, 14, 28 and Months 2, 3, 4, 7, 10, and 12"},{"measure":"Duration of Skin Rash (Folliculitis) During the First 4 Months of Treatment","description":"If the cutaneous rash was ongoing at the last visit or Month 4, the duration of cutaneous rash was calculated between start of folliculitis and Visit Month 4 or premature withdrawal visit or death.","timeFrame":"Days 0, 14, 28 and Months 2, 3, and 4"},{"measure":"Duration of Skin Rash (Folliculitis) During the Whole Treatment Period","description":"If the end of cutaneous rash was missing, the duration of cutaneous rash was calculated between start of folliculitis and last evaluation date.","timeFrame":"Days 0, 14, 28 and Months 2, 3, 4, 7, 10, and 12"},{"measure":"Percentage of Participants With Other Skin Lesions of Any Grade During the First 4 Months of Treatment","description":"Other skin lesions included presence or absence of xerosis and paronychia.","timeFrame":"Days 0, 14, 28 and Months 2, 3, and 4"},{"measure":"Percentage of Participants With Other Skin Lesions During the First 4 Months of Treatment By Type","description":"Other skin lesions included xerosis and paronychia.","timeFrame":"Days 0, 14, 28 and Months 2, 3, and 4"},{"measure":"Percentage of Participants With Other Skin Lesions During the First 4 Months of Treatment By Maximal Intensity","description":"Other skin lesions included xerosis and paronychia. Intensity was classified according to CTCAE grading. Grade 1=Macular or papular eruption or erythema without associated symptoms; Grade 2=Macular or papular eruption or erythema with pruritus or other associated symptoms; localized desquamation or other lesions covering \\<50% of BSA; Grade 3=Severe, generalized erythroderma or macular, papular, or vesicular eruption; desquamation; Grade 4=Generalized exfoliative, ulcerative, or bullous dermatitis. If a participant had several skin lesions, the maximal intensity was taken into account.","timeFrame":"Days 0, 14, 28 and Months 2, 3, and 4"},{"measure":"Percentage of Participants With Erlotinib Dose Reduction by Reason for Reduction","description":"Erlotinib dose adjustment was done in case of toxicity occurrence. Keratitis, diarrhea, interstitial lung disease, and other toxic occurrences determined erlotinib dose reduction. If erlotinib was previously discontinued for skin rash or diarrhea of Grade 2 and if these symptoms of Grade 2 recurred OR if the symptoms were intolerable for the participants, erlotinib was discontinued until recovery/Grade 1 then the dose was reduced of one level of 50 mg.","timeFrame":"Days 0, 14, 28 and Months 2, 3, 4, 7, 10, and 12"},{"measure":"Percentage of Participants With Doxycycline Dose Reduction by Reason for Reduction","description":"Occurrence of folliculitis-type skin rash of Grade greater than or equal to (≥)2 led to dose modification. Continuation of treatment with doxycycline after occurrence of folliculitis-type skin rash of Grade ≥2 was upon the investigator's opinion.","timeFrame":"Days 0, 14, 28 and Months 2, 3, 4, 7, 10, and 12"},{"measure":"Percentage of Participants With Global Disease Control by Visit","description":"Disease control was determined according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria for evaluation and was defined as participants with either complete response (CR), partial response (PR), or stable disease (SD).","timeFrame":"Months 2, 4, 7, 10, and 12"},{"measure":"Percentage of Participants by Best Global Response Under Treatment","description":"Response was determined according to the RECIST criteria for evaluation and was defined as participants with either CR, PR, SD, or progression. No CR was reported.","timeFrame":"Days 0, 14, 28 and Months 2, 3, 4, 7, 10, and 12"},{"measure":"Progression-Free Survival (PFS) - Percentage of Participants With an Event","description":"PFS was defined by the time between first intake of treatment with erlotinib and disease progression or death for any cause; estimated using Kaplan-Meier method.","timeFrame":"Days 0, 14, 28 and Months 2, 3, 4, 7, 10, and 12"},{"measure":"Progression-Free Survival (PFS) - Time to Event","description":"PFS was defined by the time between first intake of treatment with erlotinib and disease progression or death for any cause; estimated using Kaplan-Meier method.","timeFrame":"Days 0, 14, 28 and Months 2, 3, 4, 7, 10, and 12"},{"measure":"Percentage of Participants Estimated to be Progression Free at 4 and 12 Months","timeFrame":"Months 4 and 12"},{"measure":"Overall Survival (OS) - Percentage of Participants With an Event","description":"OS was defined by the time between first intake of treatment with erlotinib and death for any cause; analyzed using Kaplan-Meier method.","timeFrame":"Days 0, 14, 28 and Months 2, 3, 4, 7, 10, and 12"},{"measure":"Overall Survival (OS) - Time to Event","description":"OS was defined by the time between first intake of treatment with erlotinib and death for any cause; analyzed using Kaplan-Meier method.","timeFrame":"Days 0, 14, 28 and Months 2, 3, 4, 7, 10, and 12"},{"measure":"Percentage of Participants Estimated to be Alive at 4 and 12 Months","timeFrame":"Months 4 and 12"},{"measure":"Dermatology Life Quality Index (DLQI) Global Score","description":"Quality of life was assessed by participant's responses to a DLQI questionnaire. The DLQI is a 10-item questionnaire assessing quality of life; questions were assessed on a 4-point scale (0=not at all; 1=a little; 2=a lot; and 3=very much). The DLQI was calculated by summing the score of each question resulting in a maximum of 30 (extremely large effect on participant's life) and a minimum of 0 (no effect at all on participant's life). The higher the score, the more quality of life is impaired. Analysis was performed by visit well as at the last available value after baseline (Endpoint); change from baseline to endpoint was also determined.","timeFrame":"Baseline, Days 14 and 28 and Months 2, 3, and 4"},{"measure":"Percentage of Participants by DLQI Global Score Classification of Disease Effect on Quality of Life","description":"Quality of life was assessed by participant's responses to a DLQI questionnaire. The DLQI is a 10-item questionnaire assessing quality of life; questions were assessed on a 4-point scale (0=not at all; 1=a little; 2=a lot; and 3=very much). The DLQI was calculated by summing the score of each question resulting in a maximum of 30 (extremely large effect on participant's life) and a minimum of 0 (no effect at all on participant's life). The higher the score, the more quality of life is impaired. The DLQI global score was classified into 5 levels: 0-1 (no effect at all), 2-5 (small effect), 6-10 (moderate effect), 11-20 (very large effect) and 21-30 (extremely large effect).","timeFrame":"Baseline, Days 14 and 28 and Months 2, 3, and 4"},{"measure":"Quality of Life Score as Assessed by Visual Analog Scale (VAS)","description":"Quality of life was assessed by participant's responses to a VAS questionnaire - (evaluation of satisfaction with skin status). VAS was measured on a 100 millimeter (mm) scale where 0 = not at all satisfied and 100 = very satisfied. Participants were asked to mark the line corresponding to their satisfaction at each visit and the distance from the left edge was measured. A negative change from baseline indicates improvement. Analysis was performed by visit well as at the last available value after baseline (Endpoint).","timeFrame":"Baseline, Days 14 and 28, and Months 2, 3, and 4"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* adult patients, 18-75 years of age;\n* confirmed non-small cell lung cancer;\n* failure after first line chemotherapy for advanced disease, and scheduled for second line therapy with Tarceva.\n\nExclusion Criteria:\n\n* rash of any etiology at study entry;\n* history of significant heart disease;\n* any other malignancies (other than adequately treated squamous cell skin cancer, or in situ cancer of the cervix);\n* history of allergic reactions to tetracyclines.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Clinical Trials","affiliation":"Hoffmann-La Roche","role":"STUDY_DIRECTOR"}],"locations":[{"city":"Antibes","zip":"06600","country":"France","geoPoint":{"lat":43.58127,"lon":7.12487}},{"city":"Bordeaux","zip":"33076","country":"France","geoPoint":{"lat":44.84124,"lon":-0.58046}},{"city":"Bordeaux","zip":"33300","country":"France","geoPoint":{"lat":44.84124,"lon":-0.58046}},{"city":"Brest","zip":"29200","country":"France","geoPoint":{"lat":48.39029,"lon":-4.48628}},{"city":"Caen","zip":"14076","country":"France","geoPoint":{"lat":49.18585,"lon":-0.35912}},{"city":"Chalon-sur-Saône","zip":"71100","country":"France","geoPoint":{"lat":46.78112,"lon":4.85372}},{"city":"Chartres","zip":"28018","country":"France","geoPoint":{"lat":48.44685,"lon":1.48925}},{"city":"Draguignan","zip":"83007","country":"France","geoPoint":{"lat":43.53692,"lon":6.46458}},{"city":"Gap","zip":"05007","country":"France","geoPoint":{"lat":44.55858,"lon":6.07868}},{"city":"Gleizé","zip":"69400","country":"France","geoPoint":{"lat":45.98916,"lon":4.69708}},{"city":"Limoges","zip":"87042","country":"France","geoPoint":{"lat":45.83362,"lon":1.24759}},{"city":"Metz","zip":"57038","country":"France","geoPoint":{"lat":49.11911,"lon":6.17269}},{"city":"Nîmes","zip":"30900","country":"France","geoPoint":{"lat":43.83665,"lon":4.35788}},{"city":"Paris","zip":"75116","country":"France","geoPoint":{"lat":48.85341,"lon":2.3488}},{"city":"Paris","zip":"75674","country":"France","geoPoint":{"lat":48.85341,"lon":2.3488}},{"city":"Paris","zip":"75679","country":"France","geoPoint":{"lat":48.85341,"lon":2.3488}},{"city":"Perpignan","zip":"66000","country":"France","geoPoint":{"lat":42.69764,"lon":2.89541}},{"city":"Périgueux","zip":"24000","country":"France","geoPoint":{"lat":45.18691,"lon":0.71439}},{"city":"Pierre-Bénite","zip":"69495","country":"France","geoPoint":{"lat":45.70359,"lon":4.82424}},{"city":"Pontoise","zip":"95300","country":"France","geoPoint":{"lat":49.05,"lon":2.1}},{"city":"Rennes","zip":"35033","country":"France","geoPoint":{"lat":48.11109,"lon":-1.67431}},{"city":"Rouen","zip":"76000","country":"France","geoPoint":{"lat":49.44313,"lon":1.09932}},{"city":"Tours","zip":"37044","country":"France","geoPoint":{"lat":47.39484,"lon":0.70398}},{"city":"Vannes","zip":"56017","country":"France","geoPoint":{"lat":47.65688,"lon":-2.76205}}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Erlotinib Plus (+) Doxycycline","description":"Participants received erlotinib 150 milligrams per day (mg/day), tablets, orally (PO) until progression or unacceptable toxicity and doxycycline 100 mg/day, tablets, PO for the first 4 months of the study; after this period it was the investigator's choice to continue treatment with doxycycline."},{"id":"FG001","title":"Erlotinib","description":"Participants received erlotinib 150 mg/day, tablets, PO until progression or unacceptable toxicity."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"73"},{"groupId":"FG001","numSubjects":"74"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"11"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"66"},{"groupId":"FG001","numSubjects":"63"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"8"}]},{"type":"Progression","reasons":[{"groupId":"FG000","numSubjects":"52"},{"groupId":"FG001","numSubjects":"42"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"10"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"2"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Intent-to-Treat population (ITT): all randomized participants who received at least\n\n1 dose of erlotinib.","groups":[{"id":"BG000","title":"Erlotinib + Doxycycline","description":"Participants received erlotinib 150 mg/day, tablets, PO until progression or unacceptable toxicity and doxycycline 100 mg/day, tablets, PO for the first 4 months of the study; after this period it was the investigator's choice to continue treatment with doxycycline."},{"id":"BG001","title":"Erlotinib","description":"Participants received erlotinib 150 mg/day, tablets, PO until progression or unacceptable toxicity."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"73"},{"groupId":"BG001","value":"74"},{"groupId":"BG002","value":"147"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"63.5","spread":"10.6"},{"groupId":"BG001","value":"64.2","spread":"11.1"},{"groupId":"BG002","value":"63.8","spread":"10.8"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"25"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"49"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"48"},{"groupId":"BG001","value":"50"},{"groupId":"BG002","value":"98"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With at Least One Skin Rash (Folliculitis) of Any Grade During the First 4 Months of Treatment","description":"Description of skin rash (folliculitis, including erythema, papulo-pustules, nodule, and crust) was according to Common Terminology Criteria for Adverse Events (CTCAE) version 3 scale. Medical pictures of the face (front and sides views) systematically, and of any region presenting with skin lesions were obtained. The pictures were reviewed by a centralized committee of evaluation.","populationDescription":"ITT population; data for 1 participant in the erlotinib treatment group were missing.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Days 0, 14, 28 and Months 2, 3, and 4","groups":[{"id":"OG000","title":"Erlotinib + Doxycycline","description":"Participants received erlotinib 150 mg/day, tablets, PO until progression or unacceptable toxicity and doxycycline 100 mg/day, tablets, PO for the first 4 months of the study; after this period it was the investigator's choice to continue treatment with doxycycline."},{"id":"OG001","title":"Erlotinib","description":"Participants received erlotinib 150 mg/day, tablets, PO until progression or unacceptable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"73"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71.2"},{"groupId":"OG001","value":"80.8"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.175","statisticalMethod":"Chi-squared"}]},{"type":"SECONDARY","title":"Number of Skin Rash (Folliculitis) Events During the First 4 Months of Treatment","description":"A cutaneous rash as folliculitis can be defined with several types including erythema, papulo-pustular and nodules.","populationDescription":"ITT population","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"rash events","timeFrame":"Days 0, 14, 28 and Months 2, 3, and 4","groups":[{"id":"OG000","title":"Erlotinib + Doxycycline","description":"Participants received erlotinib 150 mg/day, tablets, PO until progression or unacceptable toxicity and doxycycline 100 mg/day, tablets, PO for the first 4 months of the study; after this period it was the investigator's choice to continue treatment with doxycycline."},{"id":"OG001","title":"Erlotinib","description":"Participants received erlotinib 150 mg/day, tablets, PO until progression or unacceptable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"74"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57"},{"groupId":"OG001","value":"62"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Skin Rash (Folliculitis) During the First 4 Months of Treatment By Type","description":"A cutaneous rash as folliculitis can be defined with several types including erythema, papulo-pustule, nodule, and crust.","populationDescription":"ITT population","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Days 0, 14, 28 and Months 2, 3, and 4","groups":[{"id":"OG000","title":"Erlotinib + Doxycycline","description":"Participants received erlotinib 150 mg/day, tablets, PO until progression or unacceptable toxicity and doxycycline 100 mg/day, tablets, PO for the first 4 months of the study; after this period it was the investigator's choice to continue treatment with doxycycline."},{"id":"OG001","title":"Erlotinib","description":"Participants received erlotinib 150 mg/day, tablets, PO until progression or unacceptable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"74"}]}],"classes":[{"title":"Erythema","categories":[{"measurements":[{"groupId":"OG000","value":"55.8"},{"groupId":"OG001","value":"70.7"}]}]},{"title":"Papulo-pustule","categories":[{"measurements":[{"groupId":"OG000","value":"65.4"},{"groupId":"OG001","value":"72.4"}]}]},{"title":"Nodule","categories":[{"measurements":[{"groupId":"OG000","value":"1.9"},{"groupId":"OG001","value":"0"}]}]},{"title":"Crust","categories":[{"measurements":[{"groupId":"OG000","value":"9.6"},{"groupId":"OG001","value":"25.9"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Skin Rash (Folliculitis) During the First 4 Months of Treatment By Maximal Intensity","description":"Intensity of skin rashes was classified according to CTCAE grading. Grade 1 equals (=) Macular or papular eruption or erythema without associated symptoms; Grade 2=Macular or papular eruption or erythema with pruritus or other associated symptoms; localized desquamation or other lesions covering less than (\\<)50 percent (%) of body surface area (BSA); Grade 3=Severe, generalized erythroderma or macular, papular, or vesicular eruption; desquamation.","populationDescription":"ITT population; only participants with an adverse event of skin rash (folliculitis) during the first 4 months were included in the analysis.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Days 0, 14, 28 and Months 2, 3, and 4","groups":[{"id":"OG000","title":"Erlotinib + Doxycycline","description":"Participants received erlotinib 150 mg/day, tablets, PO until progression or unacceptable toxicity and doxycycline 100 mg/day, tablets, PO for the first 4 months of the study; after this period it was the investigator's choice to continue treatment with doxycycline."},{"id":"OG001","title":"Erlotinib","description":"Participants received erlotinib 150 mg/day, tablets, PO until progression or unacceptable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"59"}]}],"classes":[{"title":"Grade 1","categories":[{"measurements":[{"groupId":"OG000","value":"61.5"},{"groupId":"OG001","value":"18.6"}]}]},{"title":"Grade 2","categories":[{"measurements":[{"groupId":"OG000","value":"34.6"},{"groupId":"OG001","value":"62.7"}]}]},{"title":"Grade 3","categories":[{"measurements":[{"groupId":"OG000","value":"3.8"},{"groupId":"OG001","value":"18.6"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Erlotinib + doxycycline vs Erlotinib: Grade 3 intensity skin rash (folliculitis)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","statisticalMethod":"Cochran-Mantel-Haenszel"}]},{"type":"SECONDARY","title":"Percentage of Participants With at Least One Skin Rash (Folliculitis) of Any Grade After the First 4 Months of Treatment","populationDescription":"ITT population","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Months 7, 10, and 12","groups":[{"id":"OG000","title":"Erlotinib + Doxycycline","description":"Participants received erlotinib 150 mg/day, tablets, PO until progression or unacceptable toxicity and doxycycline 100 mg/day, tablets, PO for the first 4 months of the study; after this period it was the investigator's choice to continue treatment with doxycycline."},{"id":"OG001","title":"Erlotinib","description":"Participants received erlotinib 150 mg/day, tablets, PO until progression or unacceptable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"74"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.7"},{"groupId":"OG001","value":"1.4"}]}]}]},{"type":"SECONDARY","title":"Number of Skin Rash (Folliculitis) Events After the First 4 Months of Treatment","description":"A cutaneous rash as folliculitis can be defined with several types including erythema, papulo-pustular and nodules.","populationDescription":"ITT population","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"rash events","timeFrame":"Months 7, 10, and 12","groups":[{"id":"OG000","title":"Erlotinib + Doxycycline","description":"Participants received erlotinib 150 mg/day, tablets, PO until progression or unacceptable toxicity and doxycycline 100 mg/day, tablets, PO for the first 4 months of the study; after this period it was the investigator's choice to continue treatment with doxycycline."},{"id":"OG001","title":"Erlotinib","description":"Participants received erlotinib 150 mg/day, tablets, PO until progression or unacceptable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"73"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Skin Rash (Folliculitis) After the First 4 Months of Treatment By Type","description":"A cutaneous rash as folliculitis can be defined with several types including erythema, papulo-pustule, nodule, and crust.","populationDescription":"ITT population","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Months 7, 10, and 12","groups":[{"id":"OG000","title":"Erlotinib + Doxycycline","description":"Participants received erlotinib 150 mg/day, tablets, PO until progression or unacceptable toxicity and doxycycline 100 mg/day, tablets, PO for the first 4 months of the study; after this period it was the investigator's choice to continue treatment with doxycycline."},{"id":"OG001","title":"Erlotinib","description":"Participants received erlotinib 150 mg/day, tablets, PO until progression or unacceptable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"74"}]}],"classes":[{"title":"Erythema","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}]},{"title":"Papulo-pustule","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}]},{"title":"Nodule","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Crust","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Skin Rash (Folliculitis) After the First 4 Months of Treatment By Intensity","description":"Intensity of skin rashes was classified according to CTCAE grading. Grade 1=Macular or papular eruption or erythema without associated symptoms; Grade 2=Macular or papular eruption or erythema with pruritus or other associated symptoms; localized desquamation or other lesions covering \\<50% of BSA; Grade 3=Severe, generalized erythroderma or macular, papular, or vesicular eruption; desquamation.","populationDescription":"ITT population","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Months 7, 10, and 12","groups":[{"id":"OG000","title":"Erlotinib + Doxycycline","description":"Participants received erlotinib 150 mg/day, tablets, PO until progression or unacceptable toxicity and doxycycline 100 mg/day, tablets, PO for the first 4 months of the study; after this period it was the investigator's choice to continue treatment with doxycycline."},{"id":"OG001","title":"Erlotinib","description":"Participants received erlotinib 150 mg/day, tablets, PO until progression or unacceptable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"74"}]}],"classes":[{"title":"Initial intensity: Grade 1","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}]},{"title":"Maximal intensity: Grade 1","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}]}]},{"type":"SECONDARY","title":"Time Free From Skin Rash (Folliculitis) During the First 4 Months of Treatment - Number of Participants With an Event","description":"Period without occurrence was determined as the number of days from the first dose of medication until the first appearance of folliculitis, analyzed using Kaplan-Meier analysis.","populationDescription":"ITT population","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Days 0, 14, 28 and Months 2, 3, and 4","groups":[{"id":"OG000","title":"Erlotinib + Doxycycline","description":"Participants received erlotinib 150 mg/day, tablets, PO until progression or unacceptable toxicity and doxycycline 100 mg/day, tablets, PO for the first 4 months of the study; after this period it was the investigator's choice to continue treatment with doxycycline."},{"id":"OG001","title":"Erlotinib","description":"Participants received erlotinib 150 mg/day, tablets, PO until progression or unacceptable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"74"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"59"}]}]}]},{"type":"SECONDARY","title":"Time Free From Skin Rash (Folliculitis) During the First 4 Months of Treatment - Time to Event","description":"Period without occurrence was determined as the number of days from the first dose of medication until the first appearance of folliculitis, analyzed using Kaplan-Meier analysis.","populationDescription":"ITT population","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"days","timeFrame":"Days 0, 14, 28 and Months 2, 3, and 4","groups":[{"id":"OG000","title":"Erlotinib + Doxycycline","description":"Participants received erlotinib 150 mg/day, tablets, PO until progression or unacceptable toxicity and doxycycline 100 mg/day, tablets, PO for the first 4 months of the study; after this period it was the investigator's choice to continue treatment with doxycycline."},{"id":"OG001","title":"Erlotinib","description":"Participants received erlotinib 150 mg/day, tablets, PO until progression or unacceptable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"74"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14","lowerLimit":"13","upperLimit":"22"},{"groupId":"OG001","value":"13","lowerLimit":"8","upperLimit":"16"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.143","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.763","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.525","ciUpperLimit":"1.109"}]},{"type":"SECONDARY","title":"Percentage of Participants Estimated to be Event Free at 4 Months","description":"Percentage of participants estimated to be without skin rash (folliculitis) at 4 months.","populationDescription":"ITT population","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Days 0, 14, 28 and Months 2, 3, and 4","groups":[{"id":"OG000","title":"Erlotinib + Doxycycline","description":"Participants received erlotinib 150 mg/day, tablets, PO until progression or unacceptable toxicity and doxycycline 100 mg/day, tablets, PO for the first 4 months of the study; after this period it was the investigator's choice to continue treatment with doxycycline."},{"id":"OG001","title":"Erlotinib","description":"Participants received erlotinib 150 mg/day, tablets, PO until progression or unacceptable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"74"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.7"},{"groupId":"OG001","value":"11.2"}]}]}]},{"type":"SECONDARY","title":"Time Free From Skin Rash (Folliculitis) During the Whole Treatment Period - Number of Participants With an Event","description":"Period without occurrence was determined as the number of days from the first dose of medication until the first appearance of folliculitis, analyzed using Kaplan-Meier analysis.","populationDescription":"ITT population","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Days 0, 14, 28 and Months 2, 3, 4, 7, 10, and 12","groups":[{"id":"OG000","title":"Erlotinib + Doxycycline","description":"Participants received erlotinib 150 mg/day, tablets, PO until progression or unacceptable toxicity and doxycycline 100 mg/day, tablets, PO for the first 4 months of the study; after this period it was the investigator's choice to continue treatment with doxycycline."},{"id":"OG001","title":"Erlotinib","description":"Participants received erlotinib 150 mg/day, tablets, PO until progression or unacceptable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"73"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53"},{"groupId":"OG001","value":"59"}]}]}]},{"type":"SECONDARY","title":"Time Free From Skin Rash (Folliculitis) During the Whole Treatment Period - Time to Event","description":"Period without occurrence was determined as the number of days from the first dose of medication until the first appearance of folliculitis, analyzed using Kaplan-Meier analysis.","populationDescription":"ITT population","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"days","timeFrame":"Days 0, 14, 28 and Months 2, 3, 4, 7, 10, and 12","groups":[{"id":"OG000","title":"Erlotinib + Doxycycline","description":"Participants received erlotinib 150 mg/day, tablets, PO until progression or unacceptable toxicity and doxycycline 100 mg/day, tablets, PO for the first 4 months of the study; after this period it was the investigator's choice to continue treatment with doxycycline."},{"id":"OG001","title":"Erlotinib","description":"Participants received erlotinib 150 mg/day, tablets, PO until progression or unacceptable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"73"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14","lowerLimit":"13","upperLimit":"22"},{"groupId":"OG001","value":"13","lowerLimit":"8","upperLimit":"16"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.153","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.769","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.529","ciUpperLimit":"1.116"}]},{"type":"SECONDARY","title":"Percentage of Participants Estimated to be Event Free at 12 Months","description":"Percentage of participants estimated to be without skin rash (folliculitis) at 12 months.","populationDescription":"ITT population","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Days 0, 14, 28 and Months 2, 3, 4, 7, 10, and 12","groups":[{"id":"OG000","title":"Erlotinib + Doxycycline","description":"Participants received erlotinib 150 mg/day, tablets, PO until progression or unacceptable toxicity and doxycycline 100 mg/day, tablets, PO for the first 4 months of the study; after this period it was the investigator's choice to continue treatment with doxycycline."},{"id":"OG001","title":"Erlotinib","description":"Participants received erlotinib 150 mg/day, tablets, PO until progression or unacceptable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"74"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.8"},{"groupId":"OG001","value":"11.2"}]}]}]},{"type":"SECONDARY","title":"Duration of Skin Rash (Folliculitis) During the First 4 Months of Treatment","description":"If the cutaneous rash was ongoing at the last visit or Month 4, the duration of cutaneous rash was calculated between start of folliculitis and Visit Month 4 or premature withdrawal visit or death.","populationDescription":"ITT Population; only participants with an event (folliculitis) were included in the analysis.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"days","timeFrame":"Days 0, 14, 28 and Months 2, 3, and 4","groups":[{"id":"OG000","title":"Erlotinib + Doxycycline","description":"Participants received erlotinib 150 mg/day, tablets, PO until progression or unacceptable toxicity and doxycycline 100 mg/day, tablets, PO for the first 4 months of the study; after this period it was the investigator's choice to continue treatment with doxycycline."},{"id":"OG001","title":"Erlotinib","description":"Participants received erlotinib 150 mg/day, tablets, PO until progression or unacceptable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"57"},{"groupId":"OG001","value":"61"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59.6","spread":"35.9"},{"groupId":"OG001","value":"60.6","spread":"33.5"}]}]}]},{"type":"SECONDARY","title":"Duration of Skin Rash (Folliculitis) During the Whole Treatment Period","description":"If the end of cutaneous rash was missing, the duration of cutaneous rash was calculated between start of folliculitis and last evaluation date.","populationDescription":"ITT Population; only participants with an event (folliculitis) were included in the analysis.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Standard Deviation","unitOfMeasure":"days","timeFrame":"Days 0, 14, 28 and Months 2, 3, 4, 7, 10, and 12","groups":[{"id":"OG000","title":"Erlotinib + Doxycycline","description":"Participants received erlotinib 150 mg/day, tablets, PO until progression or unacceptable toxicity and doxycycline 100 mg/day, tablets, PO for the first 4 months of the study; after this period it was the investigator's choice to continue treatment with doxycycline."},{"id":"OG001","title":"Erlotinib","description":"Participants received erlotinib 150 mg/day, tablets, PO until progression or unacceptable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"62"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"86.7","spread":"81.1"},{"groupId":"OG001","value":"99.3","spread":"90.5"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Other Skin Lesions of Any Grade During the First 4 Months of Treatment","description":"Other skin lesions included presence or absence of xerosis and paronychia.","populationDescription":"ITT population","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Days 0, 14, 28 and Months 2, 3, and 4","groups":[{"id":"OG000","title":"Erlotinib + Doxycycline","description":"Participants received erlotinib 150 mg/day, tablets, PO until progression or unacceptable toxicity and doxycycline 100 mg/day, tablets, PO for the first 4 months of the study; after this period it was the investigator's choice to continue treatment with doxycycline."},{"id":"OG001","title":"Erlotinib","description":"Participants received erlotinib 150 mg/day, tablets, PO until progression or unacceptable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"74"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39.7"},{"groupId":"OG001","value":"42.5"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Other Skin Lesions During the First 4 Months of Treatment By Type","description":"Other skin lesions included xerosis and paronychia.","populationDescription":"ITT population","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Days 0, 14, 28 and Months 2, 3, and 4","groups":[{"id":"OG000","title":"Erlotinib + Doxycycline","description":"Participants received erlotinib 150 mg/day, tablets, PO until progression or unacceptable toxicity and doxycycline 100 mg/day, tablets, PO for the first 4 months of the study; after this period it was the investigator's choice to continue treatment with doxycycline."},{"id":"OG001","title":"Erlotinib","description":"Participants received erlotinib 150 mg/day, tablets, PO until progression or unacceptable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"74"}]}],"classes":[{"title":"Xerosis","categories":[{"measurements":[{"groupId":"OG000","value":"37.0"},{"groupId":"OG001","value":"41.1"}]}]},{"title":"Paronychia","categories":[{"measurements":[{"groupId":"OG000","value":"6.8"},{"groupId":"OG001","value":"8.2"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Other Skin Lesions During the First 4 Months of Treatment By Maximal Intensity","description":"Other skin lesions included xerosis and paronychia. Intensity was classified according to CTCAE grading. Grade 1=Macular or papular eruption or erythema without associated symptoms; Grade 2=Macular or papular eruption or erythema with pruritus or other associated symptoms; localized desquamation or other lesions covering \\<50% of BSA; Grade 3=Severe, generalized erythroderma or macular, papular, or vesicular eruption; desquamation; Grade 4=Generalized exfoliative, ulcerative, or bullous dermatitis. If a participant had several skin lesions, the maximal intensity was taken into account.","populationDescription":"ITT population; only participants with an adverse event classified as other skin lesion during the first 4 months were included in the analysis.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Days 0, 14, 28 and Months 2, 3, and 4","groups":[{"id":"OG000","title":"Erlotinib + Doxycycline","description":"Participants received erlotinib 150 mg/day, tablets, PO until progression or unacceptable toxicity and doxycycline 100 mg/day, tablets, PO for the first 4 months of the study; after this period it was the investigator's choice to continue treatment with doxycycline."},{"id":"OG001","title":"Erlotinib","description":"Participants received erlotinib 150 mg/day, tablets, PO until progression or unacceptable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"31"}]}],"classes":[{"title":"Grade 1","categories":[{"measurements":[{"groupId":"OG000","value":"69.0"},{"groupId":"OG001","value":"29.0"}]}]},{"title":"Grade 2","categories":[{"measurements":[{"groupId":"OG000","value":"24.1"},{"groupId":"OG001","value":"51.6"}]}]},{"title":"Grade 3","categories":[{"measurements":[{"groupId":"OG000","value":"6.9"},{"groupId":"OG001","value":"16.1"}]}]},{"title":"Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3.2"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Erlotinib + doxycycline vs Erlotinib: Grade 3","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.003","statisticalMethod":"Cochran-Mantel-Haenszel"}]},{"type":"SECONDARY","title":"Percentage of Participants With Erlotinib Dose Reduction by Reason for Reduction","description":"Erlotinib dose adjustment was done in case of toxicity occurrence. Keratitis, diarrhea, interstitial lung disease, and other toxic occurrences determined erlotinib dose reduction. If erlotinib was previously discontinued for skin rash or diarrhea of Grade 2 and if these symptoms of Grade 2 recurred OR if the symptoms were intolerable for the participants, erlotinib was discontinued until recovery/Grade 1 then the dose was reduced of one level of 50 mg.","populationDescription":"ITT population; only participants that discontinued or interrupted erlotinib were included in the analysis.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Days 0, 14, 28 and Months 2, 3, 4, 7, 10, and 12","groups":[{"id":"OG000","title":"Erlotinib + Doxycycline","description":"Participants received erlotinib 150 mg/day, tablets, PO until progression or unacceptable toxicity and doxycycline 100 mg/day, tablets, PO for the first 4 months of the study; after this period it was the investigator's choice to continue treatment with doxycycline."},{"id":"OG001","title":"Erlotinib","description":"Participants received erlotinib 150 mg/day, tablets, PO until progression or unacceptable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"32"}]}],"classes":[{"title":"Adverse event","categories":[{"measurements":[{"groupId":"OG000","value":"80.0"},{"groupId":"OG001","value":"85.7"}]}]},{"title":"Investigator's decision","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2.4"}]}]},{"title":"Other","categories":[{"measurements":[{"groupId":"OG000","value":"20.0"},{"groupId":"OG001","value":"11.9"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Doxycycline Dose Reduction by Reason for Reduction","description":"Occurrence of folliculitis-type skin rash of Grade greater than or equal to (≥)2 led to dose modification. Continuation of treatment with doxycycline after occurrence of folliculitis-type skin rash of Grade ≥2 was upon the investigator's opinion.","populationDescription":"ITT population; only participants that discontinued or interrupted doxycycline were included in the analysis.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Days 0, 14, 28 and Months 2, 3, 4, 7, 10, and 12","groups":[{"id":"OG000","title":"Erlotinib + Doxycycline","description":"Participants received erlotinib 150 mg/day, tablets, PO until progression or unacceptable toxicity and doxycycline 100 mg/day, tablets, PO for the first 4 months of the study; after this period it was the investigator's choice to continue treatment with doxycycline."},{"id":"OG001","title":"Erlotinib","description":"Participants received erlotinib 150 mg/day, tablets, PO until progression or unacceptable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"0"}]}],"classes":[{"title":"Adverse event","categories":[{"measurements":[{"groupId":"OG000","value":"50.0"}]}]},{"title":"Other","categories":[{"measurements":[{"groupId":"OG000","value":"50.0"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Global Disease Control by Visit","description":"Disease control was determined according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria for evaluation and was defined as participants with either complete response (CR), partial response (PR), or stable disease (SD).","populationDescription":"ITT population; number (n) = number of participants analyzed for the specified parameter at a given visit.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Months 2, 4, 7, 10, and 12","groups":[{"id":"OG000","title":"Erlotinib + Doxycycline","description":"Participants received erlotinib 150 mg/day, tablets, PO until progression or unacceptable toxicity and doxycycline 100 mg/day, tablets, PO for the first 4 months of the study; after this period it was the investigator's choice to continue treatment with doxycycline."},{"id":"OG001","title":"Erlotinib","description":"Participants received erlotinib 150 mg/day, tablets, PO until progression or unacceptable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"33"}]}],"classes":[{"title":"Month 2 (n=34,33)","categories":[{"measurements":[{"groupId":"OG000","value":"88.2"},{"groupId":"OG001","value":"93.9"}]}]},{"title":"Month 4 (n=19,25)","categories":[{"measurements":[{"groupId":"OG000","value":"89.5"},{"groupId":"OG001","value":"80.0"}]}]},{"title":"Month 7 (n=11,17)","categories":[{"measurements":[{"groupId":"OG000","value":"72.7"},{"groupId":"OG001","value":"76.5"}]}]},{"title":"Month 10 (n=7,12)","categories":[{"measurements":[{"groupId":"OG000","value":"100.0"},{"groupId":"OG001","value":"66.7"}]}]},{"title":"Month 12 (n=7,10)","categories":[{"measurements":[{"groupId":"OG000","value":"71.4"},{"groupId":"OG001","value":"40.0"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants by Best Global Response Under Treatment","description":"Response was determined according to the RECIST criteria for evaluation and was defined as participants with either CR, PR, SD, or progression. No CR was reported.","populationDescription":"ITT Population","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Days 0, 14, 28 and Months 2, 3, 4, 7, 10, and 12","groups":[{"id":"OG000","title":"Erlotinib + Doxycycline","description":"Participants received erlotinib 150 mg/day, tablets, PO until progression or unacceptable toxicity and doxycycline 100 mg/day, tablets, PO for the first 4 months of the study; after this period it was the investigator's choice to continue treatment with doxycycline."},{"id":"OG001","title":"Erlotinib","description":"Participants received erlotinib 150 mg/day, tablets, PO until progression or unacceptable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"58"}]}],"classes":[{"title":"PR","categories":[{"measurements":[{"groupId":"OG000","value":"15.5"},{"groupId":"OG001","value":"10.3"}]}]},{"title":"SD","categories":[{"measurements":[{"groupId":"OG000","value":"36.2"},{"groupId":"OG001","value":"48.3"}]}]},{"title":"Progression","categories":[{"measurements":[{"groupId":"OG000","value":"48.3"},{"groupId":"OG001","value":"41.4"}]}]}]},{"type":"SECONDARY","title":"Progression-Free Survival (PFS) - Percentage of Participants With an Event","description":"PFS was defined by the time between first intake of treatment with erlotinib and disease progression or death for any cause; estimated using Kaplan-Meier method.","populationDescription":"ITT Population","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Days 0, 14, 28 and Months 2, 3, 4, 7, 10, and 12","groups":[{"id":"OG000","title":"Erlotinib + Doxycycline","description":"Participants received erlotinib 150 mg/day, tablets, PO until progression or unacceptable toxicity and doxycycline 100 mg/day, tablets, PO for the first 4 months of the study; after this period it was the investigator's choice to continue treatment with doxycycline."},{"id":"OG001","title":"Erlotinib","description":"Participants received erlotinib 150 mg/day, tablets, PO until progression or unacceptable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"74"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91.8"},{"groupId":"OG001","value":"87.8"}]}]}]},{"type":"SECONDARY","title":"Progression-Free Survival (PFS) - Time to Event","description":"PFS was defined by the time between first intake of treatment with erlotinib and disease progression or death for any cause; estimated using Kaplan-Meier method.","populationDescription":"ITT Population","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"days","timeFrame":"Days 0, 14, 28 and Months 2, 3, 4, 7, 10, and 12","groups":[{"id":"OG000","title":"Erlotinib + Doxycycline","description":"Participants received erlotinib 150 mg/day, tablets, PO until progression or unacceptable toxicity and doxycycline 100 mg/day, tablets, PO for the first 4 months of the study; after this period it was the investigator's choice to continue treatment with doxycycline."},{"id":"OG001","title":"Erlotinib","description":"Participants received erlotinib 150 mg/day, tablets, PO until progression or unacceptable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"74"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63.0","lowerLimit":"56.0","upperLimit":"107.0"},{"groupId":"OG001","value":"70.0","lowerLimit":"56.0","upperLimit":"107.0"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Estimated to be Progression Free at 4 and 12 Months","populationDescription":"ITT Population","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Months 4 and 12","groups":[{"id":"OG000","title":"Erlotinib + Doxycycline","description":"Participants received erlotinib 150 mg/day, tablets, PO until progression or unacceptable toxicity and doxycycline 100 mg/day, tablets, PO for the first 4 months of the study; after this period it was the investigator's choice to continue treatment with doxycycline."},{"id":"OG001","title":"Erlotinib","description":"Participants received erlotinib 150 mg/day, tablets, PO until progression or unacceptable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"74"}]}],"classes":[{"title":"4 Months","categories":[{"measurements":[{"groupId":"OG000","value":"30.1"},{"groupId":"OG001","value":"31.0"}]}]},{"title":"12 Months","categories":[{"measurements":[{"groupId":"OG000","value":"6.3"},{"groupId":"OG001","value":"10.8"}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS) - Percentage of Participants With an Event","description":"OS was defined by the time between first intake of treatment with erlotinib and death for any cause; analyzed using Kaplan-Meier method.","populationDescription":"ITT Population","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Days 0, 14, 28 and Months 2, 3, 4, 7, 10, and 12","groups":[{"id":"OG000","title":"Erlotinib + Doxycycline","description":"Participants received erlotinib 150 mg/day, tablets, PO until progression or unacceptable toxicity and doxycycline 100 mg/day, tablets, PO for the first 4 months of the study; after this period it was the investigator's choice to continue treatment with doxycycline."},{"id":"OG001","title":"Erlotinib","description":"Participants received erlotinib 150 mg/day, tablets, PO until progression or unacceptable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"74"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71.2"},{"groupId":"OG001","value":"67.6"}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS) - Time to Event","description":"OS was defined by the time between first intake of treatment with erlotinib and death for any cause; analyzed using Kaplan-Meier method.","populationDescription":"ITT Population","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"days","timeFrame":"Days 0, 14, 28 and Months 2, 3, 4, 7, 10, and 12","groups":[{"id":"OG000","title":"Erlotinib + Doxycycline","description":"Participants received erlotinib 150 mg/day, tablets, PO until progression or unacceptable toxicity and doxycycline 100 mg/day, tablets, PO for the first 4 months of the study; after this period it was the investigator's choice to continue treatment with doxycycline."},{"id":"OG001","title":"Erlotinib","description":"Participants received erlotinib 150 mg/day, tablets, PO until progression or unacceptable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"74"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"227.0","lowerLimit":"153.0","upperLimit":"282.0"},{"groupId":"OG001","value":"251.0","lowerLimit":"152.0","upperLimit":"336.0"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Estimated to be Alive at 4 and 12 Months","populationDescription":"ITT Population","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Months 4 and 12","groups":[{"id":"OG000","title":"Erlotinib + Doxycycline","description":"Participants received erlotinib 150 mg/day, tablets, PO until progression or unacceptable toxicity and doxycycline 100 mg/day, tablets, PO for the first 4 months of the study; after this period it was the investigator's choice to continue treatment with doxycycline."},{"id":"OG001","title":"Erlotinib","description":"Participants received erlotinib 150 mg/day, tablets, PO until progression or unacceptable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"74"}]}],"classes":[{"title":"4 Months","categories":[{"measurements":[{"groupId":"OG000","value":"68.5"},{"groupId":"OG001","value":"69.7"}]}]},{"title":"12 Months","categories":[{"measurements":[{"groupId":"OG000","value":"27.1"},{"groupId":"OG001","value":"33.5"}]}]}]},{"type":"SECONDARY","title":"Dermatology Life Quality Index (DLQI) Global Score","description":"Quality of life was assessed by participant's responses to a DLQI questionnaire. The DLQI is a 10-item questionnaire assessing quality of life; questions were assessed on a 4-point scale (0=not at all; 1=a little; 2=a lot; and 3=very much). The DLQI was calculated by summing the score of each question resulting in a maximum of 30 (extremely large effect on participant's life) and a minimum of 0 (no effect at all on participant's life). The higher the score, the more quality of life is impaired. Analysis was performed by visit well as at the last available value after baseline (Endpoint); change from baseline to endpoint was also determined.","populationDescription":"ITT Population; n=number of participants assessed for the specified parameter at a given visit.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Baseline, Days 14 and 28 and Months 2, 3, and 4","groups":[{"id":"OG000","title":"Erlotinib + Doxycycline","description":"Participants received erlotinib 150 mg/day, tablets, PO until progression or unacceptable toxicity and doxycycline 100 mg/day, tablets, PO for the first 4 months of the study; after this period it was the investigator's choice to continue treatment with doxycycline."},{"id":"OG001","title":"Erlotinib","description":"Participants received erlotinib 150 mg/day, tablets, PO until progression or unacceptable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"69"}]}],"classes":[{"title":"Baseline (n=67,69)","categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"0.5"},{"groupId":"OG001","value":"0.2","spread":"0.6"}]}]},{"title":"Day 14 (n=63,62)","categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":"3.2"},{"groupId":"OG001","value":"3.7","spread":"4.3"}]}]},{"title":"Day 28 (n=60,56)","categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":"2.5"},{"groupId":"OG001","value":"3.4","spread":"4.0"}]}]},{"title":"Month 2 (n=35,37)","categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":"4.1"},{"groupId":"OG001","value":"4.3","spread":"5.3"}]}]},{"title":"Month 3 (n=29,27)","categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":"2.7"},{"groupId":"OG001","value":"3.2","spread":"3.7"}]}]},{"title":"Month 4 (n=19,24)","categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":"3.0"},{"groupId":"OG001","value":"2.6","spread":"3.5"}]}]},{"title":"Endpoint (n=65,63)","categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":"3.3"},{"groupId":"OG001","value":"3.4","spread":"4.8"}]}]},{"title":"Change at Endpoint (n=35,37)","categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":"3.3"},{"groupId":"OG001","value":"3.2","spread":"4.8"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants by DLQI Global Score Classification of Disease Effect on Quality of Life","description":"Quality of life was assessed by participant's responses to a DLQI questionnaire. The DLQI is a 10-item questionnaire assessing quality of life; questions were assessed on a 4-point scale (0=not at all; 1=a little; 2=a lot; and 3=very much). The DLQI was calculated by summing the score of each question resulting in a maximum of 30 (extremely large effect on participant's life) and a minimum of 0 (no effect at all on participant's life). The higher the score, the more quality of life is impaired. The DLQI global score was classified into 5 levels: 0-1 (no effect at all), 2-5 (small effect), 6-10 (moderate effect), 11-20 (very large effect) and 21-30 (extremely large effect).","populationDescription":"ITT Population; n=number of participants assessed for the specified parameter at a given visit.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Baseline, Days 14 and 28 and Months 2, 3, and 4","groups":[{"id":"OG000","title":"Erlotinib + Doxycycline","description":"Participants received erlotinib 150 mg/day, tablets, PO until progression or unacceptable toxicity and doxycycline 100 mg/day, tablets, PO for the first 4 months of the study; after this period it was the investigator's choice to continue treatment with doxycycline."},{"id":"OG001","title":"Erlotinib","description":"Participants received erlotinib 150 mg/day, tablets, PO until progression or unacceptable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"69"}]}],"classes":[{"title":"Baseline, no effect (n=67,69)","categories":[{"measurements":[{"groupId":"OG000","value":"98.5","spread":"0.5"},{"groupId":"OG001","value":"97.1","spread":"0.6"}]}]},{"title":"Baseline, small effect (n=67,69)","categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":"3.2"},{"groupId":"OG001","value":"2.9","spread":"4.3"}]}]},{"title":"Day 14, no effect (n=63,62)","categories":[{"measurements":[{"groupId":"OG000","value":"69.8","spread":"2.5"},{"groupId":"OG001","value":"41.9","spread":"4.0"}]}]},{"title":"Day 14, small effect (n=63,62)","categories":[{"measurements":[{"groupId":"OG000","value":"27.0","spread":"3.3"},{"groupId":"OG001","value":"30.6","spread":"4.8"}]}]},{"title":"Day 14, moderate effect (n=63,62)","categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"4.1"},{"groupId":"OG001","value":"21.0","spread":"5.3"}]}]},{"title":"Day 14, very large effect (n=63,62)","categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":"2.7"},{"groupId":"OG001","value":"6.5","spread":"3.7"}]}]},{"title":"Day 14, extremely large effect (n=63,62)","categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":"3.0"},{"groupId":"OG001","value":"0.0","spread":"3.5"}]}]},{"title":"Day 28, no effect (n=60,56)","categories":[{"measurements":[{"groupId":"OG000","value":"66.7"},{"groupId":"OG001","value":"41.1"}]}]},{"title":"Day 28, small effect (n=60,56)","categories":[{"measurements":[{"groupId":"OG000","value":"25.0"},{"groupId":"OG001","value":"35.7"}]}]},{"title":"Day 28, moderate effect (n=60,56)","categories":[{"measurements":[{"groupId":"OG000","value":"8.3"},{"groupId":"OG001","value":"19.6"}]}]},{"title":"Day 28, very large effect (n=60,56)","categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"1.8"}]}]},{"title":"Day 28, extremely large effect (n=60,56)","categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"1.8"}]}]},{"title":"Month 2, no effect (n=35,37)","categories":[{"measurements":[{"groupId":"OG000","value":"65.7"},{"groupId":"OG001","value":"40.5"}]}]},{"title":"Month 2, small effect (n=35,37)","categories":[{"measurements":[{"groupId":"OG000","value":"22.9"},{"groupId":"OG001","value":"27.0"}]}]},{"title":"Month 2, moderate effect (n=35,37)","categories":[{"measurements":[{"groupId":"OG000","value":"5.7"},{"groupId":"OG001","value":"21.6"}]}]},{"title":"Month 2, very large effect (n=35,37)","categories":[{"measurements":[{"groupId":"OG000","value":"5.7"},{"groupId":"OG001","value":"8.1"}]}]},{"title":"Month 2, extremely large effect (n=35,37)","categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"2.7"}]}]},{"title":"Month 3, no effect (n=29,27)","categories":[{"measurements":[{"groupId":"OG000","value":"69.0"},{"groupId":"OG001","value":"37.0"}]}]},{"title":"Month 3, small effect (n=29,27)","categories":[{"measurements":[{"groupId":"OG000","value":"27.6"},{"groupId":"OG001","value":"44.4"}]}]},{"title":"Month 3, moderate effect (n=29,27)","categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"11.1"}]}]},{"title":"Month 3, very large effect (n=29,27)","categories":[{"measurements":[{"groupId":"OG000","value":"3.4"},{"groupId":"OG001","value":"7.4"}]}]},{"title":"Month 4, no effect (n=19,24)","categories":[{"measurements":[{"groupId":"OG000","value":"78.9"},{"groupId":"OG001","value":"50.0"}]}]},{"title":"Month 4, small effect (n=19,24)","categories":[{"measurements":[{"groupId":"OG000","value":"15.8"},{"groupId":"OG001","value":"41.7"}]}]},{"title":"Month 4, very large effect (n=19,24)","categories":[{"measurements":[{"groupId":"OG000","value":"5.3"},{"groupId":"OG001","value":"8.3"}]}]}]},{"type":"SECONDARY","title":"Quality of Life Score as Assessed by Visual Analog Scale (VAS)","description":"Quality of life was assessed by participant's responses to a VAS questionnaire - (evaluation of satisfaction with skin status). VAS was measured on a 100 millimeter (mm) scale where 0 = not at all satisfied and 100 = very satisfied. Participants were asked to mark the line corresponding to their satisfaction at each visit and the distance from the left edge was measured. A negative change from baseline indicates improvement. Analysis was performed by visit well as at the last available value after baseline (Endpoint).","populationDescription":"ITT population; n=number of participants assessed for the specified parameter at a given visit.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mm","timeFrame":"Baseline, Days 14 and 28, and Months 2, 3, and 4","groups":[{"id":"OG000","title":"Erlotinib + Doxycycline","description":"Participants received erlotinib 150 mg/day, tablets, PO until progression or unacceptable toxicity and doxycycline 100 mg/day, tablets, PO for the first 4 months of the study; after this period it was the investigator's choice to continue treatment with doxycycline."},{"id":"OG001","title":"Erlotinib","description":"Participants received erlotinib 150 mg/day, tablets, PO until progression or unacceptable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"68"}]}],"classes":[{"title":"Baseline (n=64,68)","categories":[{"measurements":[{"groupId":"OG000","value":"81.4","spread":"23.7"},{"groupId":"OG001","value":"87.8","spread":"19.6"}]}]},{"title":"Day 14 (n=62,63)","categories":[{"measurements":[{"groupId":"OG000","value":"68.8","spread":"26.6"},{"groupId":"OG001","value":"51.0","spread":"34.5"}]}]},{"title":"Change at Day 14 (n=59,61)","categories":[{"measurements":[{"groupId":"OG000","value":"-16.2","spread":"28.5"},{"groupId":"OG001","value":"-39.2","spread":"37.8"}]}]},{"title":"Day 28 (n=59,56)","categories":[{"measurements":[{"groupId":"OG000","value":"66.5","spread":"27.2"},{"groupId":"OG001","value":"54.8","spread":"27.0"}]}]},{"title":"Change at Day 28 (n=55,54)","categories":[{"measurements":[{"groupId":"OG000","value":"-15.5","spread":"28.8"},{"groupId":"OG001","value":"-35.1","spread":"27.8"}]}]},{"title":"Month 2 (n=36,36)","categories":[{"measurements":[{"groupId":"OG000","value":"68.9","spread":"22.8"},{"groupId":"OG001","value":"52.6","spread":"27.4"}]}]},{"title":"Month 3 (n=28,27)","categories":[{"measurements":[{"groupId":"OG000","value":"63.5","spread":"21.4"},{"groupId":"OG001","value":"56.1","spread":"31.7"}]}]},{"title":"Month 4 (n=18,24)","categories":[{"measurements":[{"groupId":"OG000","value":"71.8","spread":"20.9"},{"groupId":"OG001","value":"59.9","spread":"29.7"}]}]},{"title":"Endpoint (n=65,64)","categories":[{"measurements":[{"groupId":"OG000","value":"64.0","spread":"26.6"},{"groupId":"OG001","value":"58.3","spread":"30.8"}]}]},{"title":"Change at Endpoint (n=60,62)","categories":[{"measurements":[{"groupId":"OG000","value":"-18.1","spread":"27.7"},{"groupId":"OG001","value":"-30.4","spread":"31.4"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"Adverse events (AEs) were recorded continuously until 30 days after the last treatment administration.","eventGroups":[{"id":"EG000","title":"Erlotinib + Doxycycline","description":"Participants received erlotinib 150 mg/day, tablets, PO until progression or unacceptable toxicity and doxycycline 100 mg/day, tablets, PO for the first 4 months of the study; after this period it was the investigator's choice to continue treatment with doxycycline.","seriousNumAffected":18,"seriousNumAtRisk":73,"otherNumAffected":71,"otherNumAtRisk":73},{"id":"EG001","title":"Erlotinib","description":"Participants received erlotinib 150 mg/day, tablets, PO until progression or unacceptable toxicity.","seriousNumAffected":24,"seriousNumAtRisk":74,"otherNumAffected":69,"otherNumAtRisk":74}],"seriousEvents":[{"term":"Myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":73},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":73},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Colonic obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":73},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Staphylococcal skin infection","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":73},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Pericarditis","organSystem":"Cardiac disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":73},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"General physical health deterioration","organSystem":"General disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":73},{"groupId":"EG001","numAffected":6,"numAtRisk":74}]},{"term":"Myocardial ischaemia","organSystem":"Cardiac disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":73},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Intracranial pressure increased","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":73},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Cardiac failure","organSystem":"Cardiac disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":73},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Rectal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":73},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Lung disorder","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":73},{"groupId":"EG001","numAffected":4,"numAtRisk":74}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Bronchitis chronic","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Folliculitis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Xerosis","organSystem":"General disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Phlebitis","organSystem":"Vascular disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":73},{"groupId":"EG001","numAffected":3,"numAtRisk":74}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Rhabdomyolysis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Oesophageal achalasia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Overdose","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Sciatica","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]}],"otherEvents":[{"term":"Folliculitis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":53,"numAtRisk":73},{"groupId":"EG001","numAffected":58,"numAtRisk":74}]},{"term":"Paronychia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":73},{"groupId":"EG001","numAffected":6,"numAtRisk":74}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":73},{"groupId":"EG001","numAffected":3,"numAtRisk":74}]},{"term":"Hypertrichosis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":73},{"groupId":"EG001","numAffected":2,"numAtRisk":74}]},{"term":"Nail disorder","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":73},{"groupId":"EG001","numAffected":2,"numAtRisk":74}]},{"term":"Intertrigo","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":73},{"groupId":"EG001","numAffected":2,"numAtRisk":74}]},{"term":"Hyperkeratosis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":73},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Ingrowing nail","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":73},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Skin discolouration","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":26,"numAtRisk":73},{"groupId":"EG001","numAffected":34,"numAtRisk":74}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":73},{"groupId":"EG001","numAffected":8,"numAtRisk":74}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":73},{"groupId":"EG001","numAffected":8,"numAtRisk":74}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":73},{"groupId":"EG001","numAffected":5,"numAtRisk":74}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":73},{"groupId":"EG001","numAffected":2,"numAtRisk":74}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Aphthous stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":73},{"groupId":"EG001","numAffected":3,"numAtRisk":74}]},{"term":"Gastrooesophageal reflux disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":73},{"groupId":"EG001","numAffected":2,"numAtRisk":74}]},{"term":"Gastrointestinal disorder","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":73},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":73},{"groupId":"EG001","numAffected":3,"numAtRisk":74}]},{"term":"Haemorrhoids","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Abdominal rigidity","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Aerophagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Dry mouth","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":73},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":73},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":73},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Faecaloma","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Gingival bleeding","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Gingival hypertrophy","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Gingival pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Gingivitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Glossitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Haematemesis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Hiatus hernia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":73},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Inguinal hernia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Salivary hypersecretion","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Subileus","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":73},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Xerosis","organSystem":"General disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":28,"numAtRisk":73},{"groupId":"EG001","numAffected":30,"numAtRisk":74}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":73},{"groupId":"EG001","numAffected":9,"numAtRisk":74}]},{"term":"General physical health deterioration","organSystem":"General disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":73},{"groupId":"EG001","numAffected":4,"numAtRisk":74}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":73},{"groupId":"EG001","numAffected":2,"numAtRisk":74}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":73},{"groupId":"EG001","numAffected":2,"numAtRisk":74}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":73},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Catheter site inflammation","organSystem":"General disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":73},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Hyperthermia","organSystem":"General disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":73},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":73},{"groupId":"EG001","numAffected":2,"numAtRisk":74}]},{"term":"Fungal skin infection","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":73},{"groupId":"EG001","numAffected":2,"numAtRisk":74}]},{"term":"Oral fungal infection","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":73},{"groupId":"EG001","numAffected":2,"numAtRisk":74}]},{"term":"Lung infection","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":73},{"groupId":"EG001","numAffected":2,"numAtRisk":74}]},{"term":"Staphylococcal infection","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Abscess","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":73},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Bronchitis viral","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":73},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Bronchopulmonary aspergillosis","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":73},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Central line infection","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":73},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Conjunctivitis infective","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":73},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Cystitis","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":73},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Ear infection","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":73},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Fungal infection","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Herpes zoster","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":73},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":73},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Oral herpes","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":73},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Pertussis","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":73},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Tonsillitis","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":73},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Vaginal infection","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":73},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Conjunctivitis","organSystem":"Eye disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":73},{"groupId":"EG001","numAffected":6,"numAtRisk":74}]},{"term":"Dry eye","organSystem":"Eye disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Eye pruritus","organSystem":"Eye disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Growth of eyelashes","organSystem":"Eye disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":73},{"groupId":"EG001","numAffected":2,"numAtRisk":74}]},{"term":"Eye irritation","organSystem":"Eye disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":73},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Eye pain","organSystem":"Eye disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":73},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Keratitis","organSystem":"Eye disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Lacrimation increased","organSystem":"Eye disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Ocular hyperaemia","organSystem":"Eye disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Visual distrubance","organSystem":"Eye disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":73},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":73},{"groupId":"EG001","numAffected":2,"numAtRisk":74}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":73},{"groupId":"EG001","numAffected":2,"numAtRisk":74}]},{"term":"Bone pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":73},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Groin pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":73},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Muscular weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Neck pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":73},{"groupId":"EG001","numAffected":4,"numAtRisk":74}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Rhinitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Dysphonia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":73},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Laryngeal disorder","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Rhinorrhoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":73},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Anorexia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":73},{"groupId":"EG001","numAffected":9,"numAtRisk":74}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":73},{"groupId":"EG001","numAffected":2,"numAtRisk":74}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":73},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Diabetes mellitus inadequate control","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":73},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":73},{"groupId":"EG001","numAffected":3,"numAtRisk":74}]},{"term":"Sciatica","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":73},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Transient ischaemic attack","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":73},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Aphonia","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Dementia","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":73},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Dysarthria","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Dysgeusia","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":73},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Epiduritis","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":73},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Facial neuralgia","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Paraesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Parosmia","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":73},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Vocal cord paralysis","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":73},{"groupId":"EG001","numAffected":4,"numAtRisk":74}]},{"term":"Blood bilirubin increased","organSystem":"Investigations","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":73},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Blood alkaline phosphatase increased","organSystem":"Investigations","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Gamma-glutamyltransferase increased","organSystem":"Investigations","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Liver function test abnormal","organSystem":"Investigations","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"White blood cell count increased","organSystem":"Investigations","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":73},{"groupId":"EG001","numAffected":5,"numAtRisk":74}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":73},{"groupId":"EG001","numAffected":3,"numAtRisk":74}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":73},{"groupId":"EG001","numAffected":2,"numAtRisk":74}]},{"term":"Confusional state","organSystem":"Psychiatric disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":73},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Phlebitis","organSystem":"Vascular disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":73},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Haematoma","organSystem":"Vascular disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Orthostatic hypotension","organSystem":"Vascular disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Periphlebitis","organSystem":"Vascular disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":73},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Venous thrombosis limb","organSystem":"Vascular disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Cardiac tamponade","organSystem":"Cardiac disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":73},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Sinus tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Cytolytic hepatitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":73},{"groupId":"EG001","numAffected":3,"numAtRisk":74}]},{"term":"Cholestasis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":73},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Hyperbilirubinaemia","organSystem":"Hepatobiliary disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Eschar","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":73},{"groupId":"EG001","numAffected":2,"numAtRisk":74}]},{"term":"Rib fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Traumatic haematoma","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":73},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Vertigo","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Cerumen impaction","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Ear haemorrhage","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Renal failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":73},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Renal failure acute","organSystem":"Renal and urinary disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Adrenal insufficiency","organSystem":"Endocrine disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]},{"term":"Basal cell carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":73},{"groupId":"EG001","numAffected":0,"numAtRisk":74}]},{"term":"Vulvovaginal dryness","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":73},{"groupId":"EG001","numAffected":1,"numAtRisk":74}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"The study being conducted under this agreement is part of the overall study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study, but after the first publication or presentation that involves the overall study. Sponsor may request that confidential information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights."},"pointOfContact":{"title":"Medical Communications","organization":"Hoffmann- LaRoche","email":"genentech@druginfo.com","phone":"800-821-8590"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000069347","term":"Erlotinib Hydrochloride"}],"ancestors":[{"id":"D011799","term":"Quinazolines"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"}]}},"hasResults":true}